Recombinant Human CD270/TNFRSF14 Protein, C-hFc and His tag
- 
									
产品编号
KMH419
 - 
									
别名
肿瘤坏死因子受体超家族成员14, TR2, ATAR, HVEA, HVEM, CD270, LIGHTR, TNF receptor superfamily member 14
 - 
									
规格
- 20ug
 - 50ug
 - 100ug
 - 200ug
 - 1mg
 
 
| Catalog Number | KMH419 | 
| Alias | 肿瘤坏死因子受体超家族成员14, TR2, ATAR, HVEA, HVEM, CD270, LIGHTR, TNF receptor superfamily member 14 | 
| Size | 20ug, 50ug, 100ug, 200ug, 1mg | 
| Product Description | KMH419 Recombinant Human CD270/TNFRSF14 Protein, C-hFc and His tag contains the human TNFRSF14(39-202 aa) was expressed in Mammalian cells. | 
| Molecular Name | TNFRSF14 | 
| Product Introduction | TNFRSF14 (KMH419) 是肿瘤坏死因子受体超家族成员,参与免疫应答的调节。 | 
| Molecular Weight | 55-66 kDa | 
| Expression System | HEK293F Cells | 
| Species | Human | 
| Concentration | 联系销售经理获得最新批次的浓度 | 
| Purity | ≥95% | 
| SDS-PAGE | ![]()  | 
| Purification | Affinity Purification | 
| Uniprot ID | Q92956 | 
| Storage Condition | Store the product under sterile conditions after opening at -80℃ for 12 months. Store the lyophilized powder at -20℃. Avoid repeated freeze-thaw cycles. | 
| Formulation | PBS, pH7.5 | 
| Shipping Condition | This product is shipped on ice packs or dry ice. | 
| Background | Tumor necrosis factor receptor superfamily member 14 (herpesvirus entry mediator), also known as TNFRSF14, is the cellular receptor for TNF superfamily 14 (LIGHT). TNFRSF14 is a type I membrane protein that is considered as a Herpesvirus entry mediator. It is able to inhibit the proliferation, activation, and cytokine production of T cells. TNFRSF14 is expressed by peripheral blood T cells, B cells, monocytes and in various tissues enriched in lymphoid cells. | 
| Endotoxin | < 0.1 EU per ug | 
| Protein Family | CD molecule | 
| Biological Activity | Measured by its ability to inhibit TNF-beta - mediated cytotoxicity using L‑929 mouse fibroblast cells. The ED50 forthis effect is 2.5-10 µg/mL in the presence of 50 pg/mL of Recombinant Human TNF‑ beta /TNFSF1. | 
| Product Declaration | 该产品仅供科研使用,不可直接用于人体或注射。 | 
可以通过特定的酶活性实验、受体结合实验或细胞实验来评估蛋白的生物活性。
可以通过优化表达条件、使用适当的去污剂或分子伴侣蛋白来提高蛋白的溶解性。
							
							
							
							
						
								0